Efficacy of Amifostine in Treating Patients with Idiopathic Thrombocytopenia Purpura
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Idiopathic Thrombocytopenic Purpura (ITP) is an autoimmune disease characterized by the production of antibodies against platelet surface antigens, resulting in platelet destruction. ITP is generally treated using glucocorticoids, splenectomy, immunosuppressants, platelet transfusions, and also rituxan and rituximab. However, as these treatments are not effective in some refractory ITP patients, especially the elderly, who are also at greater risk of cerebral hemorrhage, we have undertaken this study to find a safe and effective way of treating these patients. In a clinical protocol, we have examined the efficacy of the cytoprotective adjuvant, amifostine, on 24 ITP patients, consisting of 21 Chinese (age: 13–92 years), and 3 Caucasians (age: 46–73 years). In order to prevent the side effects associated with amifostine treatment, an alternative dosing and anti-emetic regimen was developed as part of this protocol, which significantly improved patient acceptance. The protocol consisted of daily intravenous infusions of amifostine 5 × 400 mg per week, for a total of 4–5 weeks. All the patients experienced a long-lasting and continuing remission, defined as platelet counts greater than 100,000. Two patients relapsed: one after an upper respiratory tract infection, and another due to Helicobacter pylori. However, both these patients had complete remission, after they were treated again with amifostine. In this clinical study, we report for the first time, the successful use of amifostine for ITP treatment in refractory patients. In conclusion, amifostine may have good therapeutic effect on ITP patients, especially in refractory and/or elderly. The long-term clinical outcome and the mechanism of action of this drug still need further investigation.
- Cines, D. B., & McMillan, R. (2005). Management of adult idiopathic thrombocytopenic purpura. Annual Review of Medicine, 56, 425–442. CrossRef
- McMillan, R., Wang, L., Tomer, A., Nichol, J., & Pistillo, J. (2004). Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood, 103, 1364–1369. CrossRef
- Stevens, W., Koene, H., Zwaginga, J. J., & Vreugdenhil, G. (2006). Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Netherlands Journal of Medicine, 64, 356–363.
- Bussel, J. B. (2009). Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat. Hematology/Oncology Clinics of North America, 23, 1329–1341. CrossRef
- Rodeghiero, F. (2008). First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. European Journal of Haematology. Supplementum, 69, 19–26.
- Culy, C. R., & Spencer, C. M. (2001). Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs, 61, 641–684. CrossRef
- Raza, A., Qawi, H., Lisak, L., Andric, T., Dar, S., et al. (2000). Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood, 95, 1580–1587.
- Li, S. X., Zhu, H. L., Lu, X. C., Fan, H., Yao, S. Q., et al. (2007). Amifostine used in the treatment of patients with myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15, 86–90.
- Lu, X. C., Zhu, H. L., Yao, S. Q., Fan, H., Zhuang, X. M., et al. (2005). Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 13, 440–442.
- Cines, D. B., & Blanchette, V. S. (2002). Immune thrombocytopenic purpura. New England Journal of Medicine, 346, 995–1008. CrossRef
- Newland, A. (2008). Emerging strategies to treat chronic immune thrombocytopenic purpura. European Journal of Haematology. Supplementum, 69, 27–33.
- Ben-Yehuda, D., Gillis, S., & Eldor, A. (1994). Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematologica, 91, 1–6. CrossRef
- Michel, M., Cooper, N., Jean, C., Frissora, C., & Bussel, J. B. (2004). Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood, 103, 890–896. CrossRef
- Bussel, J. B., Kuter, D. J., George, J. N., McMillan, R., Aledort, L. M., et al. (2006). AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. New England Journal of Medicine, 355, 1672–1681. CrossRef
- Dimopoulou, M. N., Gandhi, S., Ghevaert, C., Chakraverty, R., Fielding, A., et al. (2007). Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion. Bone Marrow Transplantation, 40, 605–606. CrossRef
- Marcu, L. G. (2009). The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. European Journal of Cancer Care (England), 18, 116–123. CrossRef
- Winczura P, Jassem J (2009) Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev.
- Santini, V., & Giles, F. J. (1999). The potential of amifostine: From cytoprotectant to therapeutic agent. Haematologica, 84, 1035–1042.
- Viniou, N., Terpos, E., Galanopoulos, A., Kritikou-Griva, E., Akel, S., et al. (2002). Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response. Annals of Hematology, 81, 182–186. CrossRef
- Fan, H., Zhu, H. L., Yao, S. Q., Lu, X. C., Zhuang, X. M., et al. (2006). Early effect of amifostine in treating aged patients with idiopathic thrombocytopenia purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 14, 301–303.
- Efficacy of Amifostine in Treating Patients with Idiopathic Thrombocytopenia Purpura
Cell Biochemistry and Biophysics
Volume 59, Issue 1 , pp 7-12
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press Inc
- Additional Links
- Idiopathic thrombocytopenia purpura
- Myelodysplastic syndrome
- Industry Sectors